Velmanase alfa

Drug Profile

Velmanase alfa

Alternative Names: ALPHA-MAN project; Lamazym; Recombinant lysosomal alpha-D-mannosidase; Recombinant lysosomal alpha-mannosidase; rhLAMAN

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Zymenex A/S
  • Class Mannosidases; Recombinant proteins
  • Mechanism of Action Alpha-mannosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha-Mannosidosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Alpha-Mannosidosis

Most Recent Events

  • 05 Oct 2016 Preregistration for Alpha-Mannosidosis (In adolescents, In children, In adults) in European Union (IV)
  • 17 Aug 2016 Chiesi Farmaceutici initiates a phase II trial for Alpha-Mannosidosis (In children) in Denmark (IV) (EudraCT2016-001988-36)
  • 31 Mar 2016 Alpha mannosidase is now called velmanase alfa (Chiesi website, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top